It has been reported that trabectedin is capable of significantly inhibiting the growth of the primary tumor, and metastasis, of osteosarcoma through exerting effects on both tumor and immune-infiltrating cells, as well as exhibiting enhanced therapeutic efficiency in combination with PD-1-blocking antibody (Ratti et al., 2017[51]). The gene discussed is PDCD1; the disease is osteosarcoma.